MiMedx Appoints Jack Howarth as Senior Vice President, Investor Relations
December 01 2020 - 9:21AM
MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an
industry leader in advanced wound care and a therapeutic biologics
company, today announced the appointment of Jack Howarth as Senior
Vice President of Investor Relations. Mr. Howarth brings to MiMedx
25 years of public relations and financial communications
experience and almost 40 years of experience in the medical device
and pharmaceutical industry.
“The advanced wound care market is growing and
we aim to continue expanding our market leadership, while raising
the bar on communicating the nuances of its evolution from a
regulatory standpoint. This coupled with our return to Nasdaq and
important milestones for our late-stage pipeline, reinforces the
need for timely and compelling communications with the investment
community,” said Timothy R. Wright, MiMedx Chief Executive Officer.
“Jack Howarth brings extensive experience in life science investor
relations to MiMedx demonstrating our commitment to communications
as a core corporate responsibility.”
“MiMedx is poised to advance the wound-healing
category and champion the pressing demands of people with unmet
medical needs. It’s a privilege to join at this moment, as the
company reemerges – renewing its category leadership and
reinforcing the importance of its pipeline of healing products,”
said Mr. Howarth.
About Jack Howarth
Mr. Howarth joins MiMedx from Antares
Pharmaceuticals, where he served as Vice President, Corporate
Affairs. Previously, he served as head of corporate and investor
relations at King Pharmaceuticals until the acquisition by Pfizer;
and held senior leadership positions in Corporate Affairs at
Alpharma, KOS Pharmaceuticals and Elan Corporation. Mr. Howarth
also held senior positions in finance and corporate development
during his nearly two decades at Warner Lambert Company, until that
company was acquired by Pfizer in June of 2000.
Mr. Howarth received his B.S. degree in
Accounting from Boston College and M.B.A. in Finance from Seton
Hall University. He also earned baccalaureate and post-graduate
certificates from the Rutgers Institute of Management and Labor
Relations and The Wharton School at the University of
Pennsylvania.
About MiMedx
MiMedx® is an industry leader in advanced
wound care and a therapeutic biologics company developing and
distributing human placental tissue allografts with
patent-protected processes for multiple sectors of healthcare. The
Company processes the human placental tissue utilizing its
proprietary PURION® process methodology, among other
processes, to produce allografts by employing aseptic processing
techniques in addition to terminal sterilization. MiMedx has
supplied over 2 million allografts, through both direct and
consignment shipments. For additional information, please
visit www.mimedx.com.
Contact Jack
HowarthInvestor
Relations770.651.9066investorrelations@mimedx.com
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024